News

Most adults with cystic fibrosis (CF) report experiences with painful or frightening medical procedures in childhood after their diagnosis, according to a U.K. study. These patients may benefit from psychosocial support from CF teams, who can ask about trauma in childhood in a safe and sensitive manner, researchers say.

Glatiramer acetate, an approved multiple sclerosis (MS) therapy, improved the effectiveness of the antibiotic tobramycin against Pseudomonas aeruginosa, a type of bacteria that commonly infects the lungs of people with cystic fibrosis (CF), a study demonstrated. The findings support glatiramer acetate as a promising antibiotic add-on therapy candidate,…

Researchers have developed a way to monitor the onset and progression of lung disease in young children with cystic fibrosis (CF) for whom lung imaging and diagnostic techniques are not well established. Testing the approach in 145 CF infants, the researchers found that about half showed signs of early-onset…

Six months of Kaftrio (elexacaftor-tezacaftor-ivacaftor), which is marketed as Trikafta in the U.S., led to marked reductions in abdominal symptoms among people with cystic fibrosis (CF), a study in Germany and the U.K. found. “To our knowledge, this is the first study assessing gastrointestinal symptoms, with a validated…

One year of Trikafta treatment for adults with cystic fibrosis (CF) post-lung transplant resulted in only limited improvements in sinus and digestive problems and was not well-tolerated, a small study found. In fact, among the 13 patients in the study, the discontinuation rate for the triple-combination therapy was 38.4%.

Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may ease acid reflux and symptoms of nasal and sinus cavity infection in cystic fibrosis (CF) patients with advanced lung disease, a U.K.-based study found. The study, “Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and…

Taking so-called CFTR modulators — medications to correct the disease-causing faulty CFTR protein in cystic fibrosis (CF) — may significantly reduce a patient’s risk of severe COVID-19, according to a study by an international team of researchers. In fact, non-lung transplant CF patients in the U.S. and the U.K. using…

Two patients have been dosed in a clinical trial testing BX004, a nebulized phage therapy designed to kill Pseudomonas aeruginosa, the most common cause of lung infections in people with cystic fibrosis (CF). The Phase 1b/2a trial (NCT05010577), which is funded by the Cystic Fibrosis Foundation and underway in…

The prevalence of cystic fibrosis (CF), used as an indicator of the number of CF carriers, was correlated with rates of COVID-19 and related mortality during the pandemic’s early stages across 37 different countries, a study showed. “This report suggests a possible contribution of the CFTR genetic profile of…

More frequent lung function tests in young people with cystic fibrosis (CF) markedly increased the diagnoses of pulmonary exacerbations — bouts of lung symptom worsening — leading to improved treatment and better lung function, a Brazilian study suggested. “The impact of such a simple initiative can be substantial and…